Handelsbanken Fonder AB Buys 81,200 Shares of Avantor, Inc. $AVTR

Handelsbanken Fonder AB increased its stake in Avantor, Inc. (NYSE:AVTR) by 41.2% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 278,500 shares of the company’s stock after purchasing an additional 81,200 shares during the quarter. Handelsbanken Fonder AB’s holdings in Avantor were worth $2,757,000 at the end of the most recent quarter.

A number of other hedge funds have also added to or reduced their stakes in the stock. EverSource Wealth Advisors LLC boosted its stake in shares of Avantor by 119.1% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,187 shares of the company’s stock worth $29,000 after buying an additional 1,189 shares during the last quarter. Strategic Wealth Investment Group LLC purchased a new stake in Avantor during the second quarter valued at $32,000. Private Trust Co. NA lifted its holdings in Avantor by 46.2% in the fourth quarter. Private Trust Co. NA now owns 2,769 shares of the company’s stock valued at $32,000 after acquiring an additional 875 shares during the period. Osaic Holdings Inc. lifted its holdings in Avantor by 60.9% in the second quarter. Osaic Holdings Inc. now owns 2,810 shares of the company’s stock valued at $38,000 after acquiring an additional 1,064 shares during the period. Finally, Los Angeles Capital Management LLC purchased a new position in Avantor in the fourth quarter worth about $32,000. 95.08% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on AVTR. Deutsche Bank Aktiengesellschaft restated a “hold” rating and set a $13.00 price target on shares of Avantor in a research note on Thursday, July 30th. Royal Bank Of Canada raised their price objective on shares of Avantor from $9.00 to $14.00 and gave the stock a “sector perform” rating in a report on Thursday, July 30th. Zacks Research upgraded shares of Avantor from a “strong sell” rating to a “hold” rating in a research report on Thursday, April 30th. Stifel Nicolaus upped their target price on shares of Avantor from $8.00 to $15.00 and gave the company a “hold” rating in a report on Thursday, July 30th. Finally, Wolfe Research raised shares of Avantor from a “strong sell” rating to a “hold” rating in a report on Thursday, July 30th. Two investment analysts have rated the stock with a Buy rating, fifteen have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Avantor currently has a consensus rating of “Hold” and a consensus target price of $12.00.

Avantor Stock Performance

Shares of AVTR opened at $13.65 on Monday. The business has a 50-day simple moving average of $11.21 and a two-hundred day simple moving average of $9.54. The company has a quick ratio of 1.18, a current ratio of 1.78 and a debt-to-equity ratio of 0.65. Avantor, Inc. has a 52 week low of $7.26 and a 52 week high of $15.93. The stock has a market cap of $9.24 billion, a price-to-earnings ratio of -16.26, a PEG ratio of 10.29 and a beta of 0.89.

Avantor (NYSE:AVTR) last posted its quarterly earnings data on Wednesday, July 29th. The company reported $0.21 earnings per share for the quarter, beating analysts’ consensus estimates of $0.19 by $0.02. The firm had revenue of $1.69 billion for the quarter, compared to analysts’ expectations of $1.61 billion. Avantor had a positive return on equity of 9.92% and a negative net margin of 8.81%.The business’s quarterly revenue was up .5% on a year-over-year basis. During the same period in the previous year, the firm earned $0.24 EPS. Avantor has set its FY 2026 guidance at 0.800-0.830 EPS. On average, analysts expect that Avantor, Inc. will post 0.81 EPS for the current year.

Avantor Profile

Avantor, Inc (NYSE:AVTR) is a global provider of mission-critical products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries. The company delivers essential solutions that support research, development, production and safety applications. Its product portfolio spans from high-purity chemicals and reagents to biologics and cell culture media, as well as lab equipment, consumables and custom manufacturing services.

Avantor’s offerings are organized across two primary segments.